Intravitreal Bevacizumab Is Associated With Prolonged Ventilatory Support in Preterm Infants With Bronchopulmonary Dysplasia

Huang, Cho-YiCho-YiHuangHSIN-CHUNG HUANGChen, Mei-HueiMei-HueiChenTSO-TING LAIHUNG-CHIEH CHOUCHIEN-YI CHENTING-AN YENCardoso, Wellington VWellington VCardosoPO-NIEN TSAO2023-01-042023-01-042022-1200123692https://scholars.lib.ntu.edu.tw/handle/123456789/626908Intravitreal bevacizumab (IVB), an anti-vascular endothelial growth factor (VEGF) antibody, is a widely adopted treatment for retinopathy of prematurity (ROP). Although animal studies have demonstrated that IVB inhibits alveologenesis in neonatal rat lung, the clinical influence of IVB on respiratory outcomes has not been studied.enbronchopulmonary dysplasia; intravitreal bevacizumab; retinopathy of prematurity; vascular endothelial growth factor[SDGs]SDG3Intravitreal Bevacizumab Is Associated With Prolonged Ventilatory Support in Preterm Infants With Bronchopulmonary Dysplasiajournal article10.1016/j.chest.2022.06.017357533852-s2.0-85139022371https://api.elsevier.com/content/abstract/scopus_id/85139022371